Vitamin D supplementation in multiple sclerosis patients in 2012: hype or reality as an adjunctive therapy?

Background Most multiple sclerosis patients on disease-modifying treatment at Umeå University Hospital are treated with rituximab and the prevalence of vitamin D supplementation has increased over time. Follow-up studies of these off-label treatments are needed. Objective To study inflammatory activity and adverse effects in rituximab-treated multiple sclerosis patients, and associations with 25-hydroxy-vitamin D levels. Methods Retrospectively collected data on repeated estimates of relapses, disability, side effects, magnetic resonance imaging, laboratory measures including 25-hydroxy-vitamin D levels and self-perceived health. Results In 272 multiple sclerosis patients with a mean follow-up of 43 months, we identified seven possible relapses during active rituximab treatment. On magnetic resonance imaging examination, new T2 lesions were seen in 1.3% (10 out of 792 scans), and 0.25% (two out of 785 scans) showed contrast enhancement. Adjusted 25-hydroxy-vitamin D levels in samples drawn close to all magnetic resonance images with new T2 lesions were lower compared to the remainder (62 vs. 81 nmol/l; P = 0.030). Levels of 25-hydroxy-vitamin D were associated with self-perceived health ( r = 0.18, P = 0.041, n = 130) and C-reactive protein ( r = –0.13, P = 0.042) but not with the risk of side effects. Conclusion The inflammatory activity in this rituximab-treated multiple sclerosis population that increasingly used vitamin D supplementation was extremely low. Higher 25-hydroxy-vitamin D levels were associated with beneficial outcomes.

Download Full-text

Vitamin D Supplementation Reduces Relapse Rate in Relapsing-Remitting Multiple Sclerosis Patients Treated With Natalizumab

Journal of Multiple Sclerosis ◽

10.4172/2376-0389.1000170 ◽

2016 ◽

Vol 03 (02) ◽

Author(s):

Julie HL ◽

Helle BS

Keyword(s):

Multiple Sclerosis ◽

Vitamin D ◽

Relapse Rate ◽

Vitamin D Supplementation ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

Multiple Sclerosis Patients ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

Vitamin D supplementation up-regulates IL-6 and IL-17A gene expression in multiple sclerosis patients

International Immunopharmacology ◽

10.1016/j.intimp.2015.06.033 ◽

2015 ◽

Vol 28 (1) ◽

pp. 414-419 ◽

Cited By ~ 23

Author(s):

Bahar Naghavi Gargari ◽

Mehrdad Behmanesh ◽

Zeinab Shirvani Farsani ◽

Majid Pahlevan Kakhki ◽

Amir Reza Azimi

Keyword(s):

Gene Expression ◽

Multiple Sclerosis ◽

Vitamin D ◽

Vitamin D Supplementation ◽

Multiple Sclerosis Patients

Download Full-text

The Compensatory Increased BDNF and NGF in Patients with Multiple Sclerosis Following Home-based Aerobic Training and Vitamin D Supplementation During COVID-19 Outbreak

10.21203/rs.3.rs-629297/v1 ◽

2021 ◽

Author(s):

Elahe Bahmani ◽

Rastegar Hoseini ◽

Ehsan Amiri

Keyword(s):

Multiple Sclerosis ◽

Vitamin D ◽

Aerobic Training ◽

Controlled Trial ◽

Vitamin D Supplementation ◽

Lifestyle Modifications ◽

Home Based ◽

Post Test ◽

Multiple Sclerosis Patients ◽

And Control

Abstract Background: Lifestyle modifications (physical activity and diet) are among the most promising strategies in MS rehabilitation. This study aimed to investigate the effect of home-based aerobic training and vitamin D supplementation in patients with multiple sclerosis during the COVID-19 outbreak.Methods: In this randomized, single-blinded, placebo-controlled trial, 38 females with Multiple sclerosis with EDSS: 3-5 (aged 20–40 years with body mass index [BMI] of 25–30 kg/m2) were randomly assigned into four groups: aerobic training + Vitamin D supplementation (AT+Vit D; n=10); aerobic training (AT; n=9); Vitamin D supplementation (Vit D; n=9), and Control (Placebo) (n=10). The AT program consisted of 50-70% of HRMax, 25-40 min/day, three days/wk for eight weeks. Participants in the Vit D group consumed 50000 IU of Vitamin D supplement capsules per week for eight weeks. The data were analyzed through paired t-test and one-way analysis of variance, as well as Tukey's post hoc test at the signification level of P<0.05.Results: BDNF and NGF levels improved significantly from pre-test to post-test within all experimental groups. BDNF and NGF decreased significantly in AT+Vit D, AT, and Vit D compared to C. Also, the results show that the AT+Vit D had significantly lower BDNF and NGF compared to AT (P=0.023 and P=0.011) and Vit D (P=0.001 and P=0.002). Conclusion: These findings suggest that the combination of AT+Vit D improves BDNF and NGF status more effectively than AT or Vit D alone in female Multiple sclerosis patients.

Download Full-text

Multiple sclerosis patients have a diminished serologic response to vitamin D supplementation compared to healthy controls

Multiple Sclerosis Journal ◽

10.1177/1352458515600248 ◽

2015 ◽

Vol 22 (6) ◽

pp. 753-760 ◽

Cited By ~ 28

Author(s):

Pavan Bhargava ◽

Sonya U Steele ◽

Emmanuelle Waubant ◽

Nisha R Revirajan ◽

Jacqueline Marcus ◽

...

Keyword(s):

Multiple Sclerosis ◽

Vitamin D ◽

Contraceptive Use ◽

Vitamin D Insufficiency ◽

Vitamin D Supplementation ◽

Healthy Controls ◽

Open Label ◽

Hydroxyvitamin D ◽

Significant Difference ◽

Multiple Sclerosis Patients

Background: Vitamin D insufficiency is a risk factor for multiple sclerosis (MS), and patients do not always show the expected response to vitamin D supplementation. Objective: We aimed to determine if vitamin D supplementation leads to a similar increase in serum 25-hydroxyvitamin-D (25(OH)D) levels in patients with MS and healthy controls (HCs). Methods: Participants in this open-label study were female, white, aged 18–60 years, had 25(OH)D levels ⩽ 75 nmol/l at screening, and had relapsing–remitting MS (RRMS) or were HCs. Participants received 5000 IU/day of vitamin D3 for 90 days. Utilizing generalized estimating equations we examined the relationship between the primary outcome (serum 25(OH)D level) and the primary (MS versus HC status) and secondary predictors. Results: For this study 27 MS patients and 30 HCs were enrolled. There was no significant difference in baseline 25(OH)D level or demographics except for higher body mass index (BMI) in the MS group (25.3 vs. 23.6 kg/m2, p=0.035). In total, 24 MS subjects and 29 HCs completed the study. In a multivariate model accounting for BMI, medication adherence, and oral contraceptive use, MS patients had a 16.7 nmol/l (95%CI: 4.2, 29.2, p=0.008) lower increase in 25(OH)D levels compared with HCs. Conclusions: Patients with MS had a lower increase in 25(OH)D levels with supplementation, even after accounting for putative confounders.

Download Full-text

Vitamin D supplementation reduces relapse rate in relapsing-remitting multiple sclerosis patients treated with natalizumab

Multiple Sclerosis and Related Disorders ◽

10.1016/j.msard.2016.10.005 ◽

2016 ◽

Vol 10 ◽

pp. 169-173 ◽

Cited By ~ 32

Author(s):

Julie Hejgaard Laursen ◽

Helle Bach Søndergaard ◽

Per Soelberg Sørensen ◽

Finn Sellebjerg ◽

Annette Bang Oturai

Keyword(s):

Multiple Sclerosis ◽

Vitamin D ◽

Relapse Rate ◽

Vitamin D Supplementation ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

Multiple Sclerosis Patients ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

Effects of Vitamin D Supplementation on Inflammatory Markers in Multiple Sclerosis Patients: A Systematic Review and Meta-Analysis

Journal of Archives in Military Medicine ◽

10.5812/jamm.112426 ◽

2021 ◽

Vol 9 (1) ◽

Author(s):

Shima Mehrabadi ◽

Elham Zahedi

Keyword(s):

Multiple Sclerosis ◽

Clinical Trial ◽

Vitamin D ◽

Randomized Clinical Trial ◽

Meta Analysis ◽

Total Sample ◽

Vitamin D Supplementation ◽

Online Databases ◽

Ifn Γ ◽

Multiple Sclerosis Patients

Context: Numerous studies have indicated that vitamin D can modulate the immune system and plays an important role in regulating immune cells’ functions. Some clinical studies have assessed the effect of vitamin D supplementation on cytokine markers in multiple sclerosis (MS) as a disease in which the immune system’s function is disrupted. Evidence Acquisition: This study was designed to assess randomized clinical trial studies evaluating the overall effect of vitamin D on the levels of IL-10, IL-17, and IFN-γ in MS patients. Methods: We searched PubMed and Scopus online databases up to November 2020 for relevant randomized clinical trial studies by using certain keywords. Eight studies from 273 articles, with a total sample of 443 participants, were considered Results: The meta-analysis indicated that vitamin D consumption did not significantly change the levels of IL-10 (WMD : -174.56, 95% CI: -373.10 to 23.98), IL-17 (WMD : -0.11, 95% CI: -0.54.10 to 0.33), or IFN-γ (WMD : 61.47, 95% CI: 43.96 to 78.98) in MS patients. Conclusions: Further clinical trials are warranted to evaluate the effects of vitamin D supplement on IL-10 and IL-17, and INFγ levels in MS patients.

Download Full-text

Vitamin D Supplementation and Mental Health in Multiple Sclerosis Patients: A Systematic Review

Nutrients ◽

10.3390/nu13124207 ◽

2021 ◽

Vol 13 (12) ◽

pp. 4207

Author(s):

Dominika Głąbska ◽

Aleksandra Kołota ◽

Katarzyna Lachowicz ◽

Dominika Skolmowska ◽

Małgorzata Stachoń ◽

...

Keyword(s):

Quality Of Life ◽

Mental Health ◽

Multiple Sclerosis ◽

Systematic Review ◽

Vitamin D ◽

Depressive Symptoms ◽

Positive Influence ◽

Vitamin D Supplementation ◽

Multiple Sclerosis Patients

Vitamin D has a promising role in multiple sclerosis (MS) management, and it has been found to be beneficial for patients’ mental health, which is reduced in MS patients. The aim of the present study was to conduct a systematic review of the literature to assess the influence of vitamin D supplementation on mental health in MS patients. The systematic review was registered in the PROSPERO database (CRD42020155779) and it was conducted on the basis of the PRISMA guidelines. The search procedure was conducted using PubMed and Web of Science databases and it included studies published up until September 2021. Six studies were included in the systematic review. The risk of bias was analyzed using the Newcastle–Ottawa Scale (NOS). Within the included studies, there were two studies randomized against placebo and four other prospective studies. The studies presented vitamin D interventions randomized against placebo or not randomized, while supplementation was applied for various durations—from 4 weeks to 12 months, or the studies compared patients who applied vitamin D supplementation and those who did not apply it and verified the effect of the supplementation after a number of years. The mental health outcomes that were assessed included quality of life, depression/depressive symptoms, and fatigue as an additional element. The majority of studies supported the positive influence of vitamin D on the mental health of MS patients, including the study characterized as having the highest quality (randomized against placebo with the highest NOS score). All the studies that assessed the quality of life indicated the positive influence of vitamin D while the studies that did not find a positive influence of vitamin D were conducted for depression/depressive symptoms. In spite of the fact that only a small number of studies have been conducted so far, and only two studies were randomized against a placebo, some conclusions may be formulated. The systematic review allowed us to conclude that there may be a positive effect of vitamin D supplementation in MS patients, which was stated in all of the studies analyzing quality of life, as well as in one study analyzing depressive symptoms. Considering that vitamin D deficiency is common in MS patients, and the potential positive influence of supplementation on the quality of life, supplementation should be applied at least in doses that cover the recommended intake.

Download Full-text